Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis

Pharmacological Research

Volumn 63, Issue 5, 2011, Pages 383-388

  Matsui, Takanori ^a   Nishino, Yuri ^a   Takeuchi, Masayoshi ^b   Yamagishi, Sho Ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

AGEs; Atherosclerosis; GLP 1; RAGE; Vildagliptin

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; GLUCOSE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P22; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE 1; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AORTA INJURY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HEART RATE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; THORACIC AORTA;

ADAMANTANE; ANIMALS; AORTA, THORACIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLYCOSYLATION END PRODUCTS, ADVANCED; MALE; NITRILES; OBESITY; PYRROLIDINES; RATS; RATS, INBRED OLETF; VASCULAR SYSTEM INJURIES;

EID: 79955480528     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2011.02.003     Document Type: Article

References (30)

1. M. Banerjee, N. Younis, and H. Soran Vildagliptin in clinical practice: a review of literature Expert Opin Pharmacother 10 2009 2745 2757
2. W. Kim, and J.M. Egan The role of incretins in glucose homeostasis and diabetes treatment Pharmacol Rev 60 2008 470 512
3. K.M. Utzschneider, J. Tong, B. Montgomery, J. Udayasankar, F. Gerchman, and S.M. Marcovina The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose Diabetes Care 31 2008 108 113
4. K. Azuma, Z. Rádiková, J. Mancino, F.G. Toledo, E. Thomas, and C. Kangani Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes J Clin Endocrinol Metab 93 2008 459 464 (Pubitemid 351240816)
5. K. Miura, Y. Kitahara, and S. Yamagishi Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats Horm Metab Res 42 2010 731 735
6. H. Vlassara, and R. Bucala Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors Diabetes Suppl 3 1996 S65 S66
7. M. Brownlee, A. Cerami, and A. Vlassara Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications N Engl J Med 318 1998 1315 1321
8. S. Rahbar Novel inhibotrs of glycation and AGE formation Cell Biochem Biophys 48 2007 147 157 (Pubitemid 47340881)
9. S.F. Yan, R. Ramasamy, and A.M. Schmidt The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature Circ Res 106 2010 842 853
10. S. Yamagishi, K. Nakamura, and T. Matsui Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease Pharmacol Res 60 2009 174 178
11. S. Yamagishi, and T. Imaizumi Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy Curr Pharm Des 11 2005 2279 2299 (Pubitemid 40872698)
12. K. Jandeleit-Dahm, and M.E. Cooper The role of AGEs in cardiovascular disease Curr Pharm Des 14 2008 979 986 (Pubitemid 351753286)
13. S. Yamagishi, K. Nakamura, T. Matsui, S. Ueda, K. Fukami, and S. Okuda Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications Expert Opin Investig Drugs 17 2008 983 996
14. S. Yamagishi, K. Nakamura, T. Matsui, Y. Noda, and T. Imaizumi Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication Curr Pharm Des 14 2008 487 495 (Pubitemid 351516853)
15. S. Yamagishi, and T. Matsui Smooth muscle cell pathophysiology and advanced glycation end products (AGEs) Curr Drug Targets 11 2010 875 881
16. Y. Ishibashi, T. Matsui, M. Takeuchi, and S. Yamagishi Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression Biochem Biophys Res Commun 391 2010 1405 1408
17. M. Takeuchi, Z. Makita, R. Bucala, T. Suzuki, T. Koike, and Y. Kameda Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo Mol Med 6 2000 114 125
18. Miura K, Kitahara Y, Kajioka T, Takeuchi M, Yamagishi S. Combination therapy with nateglinide and telmisartan ameliorates insulin resistance in zucker fatty rats by suppressing advanced glycation end product receptor axis. Horm Metab Res, in press.
19. S. Yamagishi, T. Matsui, K. Nakamura, T. Yoshida, M. Takeuchi, and H. Inoue Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats Ophthalmic Res 39 2007 92 97 (Pubitemid 46909866)
20. S. Yamagishi, K. Nakamura, T. Matsui, Y. Inagaki, K. Takenaka, and Y. Jinnouchi Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression J Biol Chem 281 2006 20213 20220 (Pubitemid 44065796)
21. Y. Ide, T. Matsui, Y. Ishibashi, M. Takeuchi, and S. Yamagishi Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation Microvasc Res 80 2010 227 232
22. T. Matsui, S. Yamagishi, M. Takeuchi, S. Ueda, K. Fukami, and S. Okuda Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression Pharmacol Res 61 2010 34 39
23. S. Yamagishi, H. Fujimori, H. Yonekura, Y. Yamamoto, and H. Yamamoto Advanced glycation end products inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells Diabetologia 41 1998 1435 1441 (Pubitemid 28551614)
24. T. Matsui, S. Yamagishi, M. Takeuchi, S. Ueda, K. Fukami, and S. Okuda Nifedipine a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation Biochem Biophys Res Commun 385 2009 269 272
25. Y. Inagaki, S. Yamagishi, T. Okamoto, M. Takeuchi, and S. Amano Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation Diabetologia 46 2003 284 287 (Pubitemid 36343893)
26. S. Yamagishi, Y. Inagaki, T. Okamoto, S. Amano, K. Koga, and M. Takeuchi Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells Kidney Int 63 2003 464 473 (Pubitemid 36126793)
27. S. Yamagishi, Y. Inagaki, T. Okamoto, S. Amano, K. Koga, and M. Takeuchi Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells J Biol Chem 277 2002 20309 20315 (Pubitemid 34967325)
28. T. Okamoto, S. Yamagishi, Y. Inagaki, S. Amano, K. Koga, and R. Abe Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin FASEB J 16 2002 1928 1930
29. B.F. Burkey, X. Li, L. Bolognese, B. Balkan, M. Mone, and M. Russell Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats J Pharmacol Exp Ther 315 2005 688 695 (Pubitemid 41500734)
30. A. Soro-Paavonen, A.M. Watson, J. Li, K. Paavonen, A. Koitka, and A.C. Calkin Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes Diabetes 57 2008 2461 2469